The category has moved in some unexpected directions, but ultimately, consumers are demanding products that fit naturally into their lifestyles, are convenient and taste good.
Elcelyx Therapeutics has secured $20 million in Series C financing to fund clinical trials of its Lovidia over-the-counter weight loss product, and NewMet for Type 2 diabetes.